A157 THE THRESHOLD FOR INFLIXIMAB TROUGH LEVELS LEADING TO DOSE ESCALATION DIFFERS BETWEEN CROHN’S DISEASE AND ULCERATIVE COLITIS

BACKGROUND: Therapeutic drug monitoring (TDM) of infliximab (IFX) provides an objective measure that allows physicians to optimize the dose for patients on biologic therapies and potentially reduce loss of response (LOR). The currently accepted therapeutic range is 3 – 7 μg/mL. With the potential fo...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Can Assoc Gastroenterol
Main Authors: Cookson, T A, Fedorak, R, Halloran, B P, Dieleman, L A, Wong, K, Huang, V, Peerani, F, Kroeker, K I
Format: Artigo
Sprog:Inglês
Udgivet: Oxford University Press 2018
Fag:
Paper Sessions
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6508180/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy009.157
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker